STOCK TITAN

MacroGenics to Participate in Upcoming Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
MacroGenics, Inc. (MGNX) announced their participation in the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference in New York. The company's President and CEO, Scott Koenig, M.D., Ph.D., will take part in a fireside chat on February 7, 2024, at 2:00 pm ET. The management will also engage in one-on-one meetings. The webcast of the presentation can be accessed on the company's Investor Relations website, with an archived replay available for 30 days.
Positive
  • None.
Negative
  • None.

ROCKVILLE, MD, Feb. 02, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following upcoming investor conference:

  • Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference (New York).  MacroGenics’ President and CEO, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Wednesday, February 7, 2024, at 2:00 pm ET. MacroGenics’ management will also participate in one-on-one meetings.

A webcast of the above presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm.  The Company will maintain an archived replay of this webcast on its website for 30 days.   

About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

###


MacroGenics is participating in the Guggenheim Healthcare Talks on February 7, 2024.

The President and CEO of MacroGenics, Scott Koenig, M.D., Ph.D., will participate in the fireside chat.

The webcast can be accessed on the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm.

The archived replay will be available on the company's website for 30 days.
Macrogenics Inc

NASDAQ:MGNX

MGNX Rankings

MGNX Latest News

MGNX Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
US
Rockville

About MGNX

a career at macrogenics could be waiting for you! please click on "careers" ---------------------------->>> to learn more. macrogenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. macrogenics creates both differentiated molecules that are directed to novel cancer targets, as well as “bio-betters,” which are drugs designed to improve upon marketed medicines. the combination of macrogenics’ technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. these are exciting times at macrogenics and we hope that you will take the opportunity to learn more about our organization, our pipeline and to view our job opportunities!